Integrating pharmacogenetic information and clinical decision support into the electronic health record

Journal of the American Medical Informatics Association

Volumn 21, Issue 3, 2014, Pages 522-528

  Goldspiel, Barry R ^a   Flegel, Willy A ^a   DiPatrizio, Gary ^a   Sissung, Tristan ^b   Adams, Sharon D ^a   Penzak, Scott R ^a   Biesecker, Leslie G ^c   Fleisher, Thomas A ^a   Patel, Jharana J ^a   Herion, David ^a   Figg, William D ^b   Lertora, Juan J L ^a   McKeeby, Jon W ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; CARBAMAZEPINE; HLA ANTIGEN;

ALGORITHM; ALLELE; ALLERGIC REACTION; ARTICLE; CLINICAL LABORATORY; DECISION SUPPORT SYSTEM; ELECTRONIC MEDICAL RECORD; GENETIC SCREENING; GENOTYPE; HLA SYSTEM; HUMAN; LABORATORY TEST; MEDICAL INFORMATION SYSTEM; MEDICAL SOCIETY; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACOGENETICS; PHARMACY AND THERAPEUTICS COMMITTEE; PRACTICE GUIDELINE; SYSTEM ANALYSIS; CLINICAL DECISION SUPPORT; COMPUTER ASSISTED DRUG THERAPY; COMPUTER INTERFACE; COMPUTERIZED PROVIDER ORDER ENTRY; GENETICS; HOSPITAL INFORMATION SYSTEM; INFORMATION SCIENCE; METHODOLOGY; PATIENT SAFETY; PERSONALIZED MEDICINE;

CLINICAL DECISION SUPPORT; COMPUTERIZED PRESCRIBER ORDER ENTRY; INFORMATICS; PATIENT SAFETY; PHARMACOGENETICS;

ALGORITHMS; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG THERAPY, COMPUTER-ASSISTED; ELECTRONIC HEALTH RECORDS; GENOTYPE; HLA ANTIGENS; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ORDER ENTRY SYSTEMS; PHARMACOGENETICS; SYSTEMS INTEGRATION; USER-COMPUTER INTERFACE;

EID: 84901827552     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2013-001873     Document Type: Article

References (25)

1. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4.
2. Table of Pharmacogenomic Biomarkers in Drug Labels. US Food and Drug Administration. http://www.fda.gov/drugs/scienceresearch/researchareas/ pharmacogenetics/ucm083378.htm (accessed 1 Apr 2013).
3. Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749-57.
4. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med 2013;15:258-67.
5. Crews KR, Hicks JK, Pui CH, et al. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012;92:467-75.
6. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011;89:464-7.
7. Approaching clinical decision support in medication management. In: Osheroff J. ed Improving medication use and outcomes with clinical decision support: a step-by-step guide. Chicago: Healthcare Information and Management Systems Society, 2009:1-10.
8. Osheroff JA, Teich JM, Middleton B, et al. A roadmap for national action on clinical decision support. J Am Med Inform Assoc 2007;14:141-5.
9. Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012;92:563-6.
10. Welch BM, Kawamoto K. Clinical decision support for genetically guided personalized medicine: a systematic review. J Am Med Inform Assoc 2013;20:388-400.
11. Peterson JF, Bowton E, Field JR, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med 2013;15:833-41.
12. Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 2014;21:e93-9.
13. Mallal S, Phillips E, Carosi G, et al.; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
14. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008;42:387-96.
15. Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012;91:734-8.
16. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43.
17. Chen P, Lin J-J, Lu C-S, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011;364:1126-33.
18. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for hla-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013;94:324-8.
19. Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics 2011;12:1741-9.
20. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013;93:153-8.
21. Adams S, Robbins FM, Chen D, et al. HLA class I and II genotype of the NCI-60 cell lines. J Transl Med 2005;3:11-19.
22. Robinson J, Halliwell JA, McWilliam H, et al. The IMGT/HLA database. Nucleic Acids Res 2013;41:D1222-7.
23. Ioannidis JPA. To replicate or not to replicate: the case of pharmacogenetic studies. Circ Cardiovasc Genet 2013;6:413-18.
24. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013;93:324-5.
25. Relling MV, Gardner EE, Sandborn WJ, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-91. Erratum in: Clin Pharmacol Ther. 2011;90:894.